毕岱总皂苷对实验性高血脂症大鼠血脂代谢的影响

目的:建立高血脂症大鼠模型,观察毕岱总皂苷(BD-TAS)对高血脂症大鼠血脂代谢的影响。方法:健康成年雄性SD大鼠60只,随机分为正常对照组(NC),高脂模型组(HC),血脂康对照组,毕岱总皂苷组(BD-TAS,低、中、高剂量组);除NC组,其余各组高脂饲料喂养8周,建立高脂血症大鼠模型;从模型复制成功后第0周开始,NC组和HC组均ig等量生理盐水,BD-TAS低、中、高剂量组(4,9,12 g.kg-1)和血脂康对照组(0.5 g.kg-1)均ig给药,并在第0,2,4,6周后称量体重,眼眶取血,离心取血清,用酶法测定血浆中胆固醇(TC)、甘油三酯(TG)和高密度脂蛋白胆固醇(HDL-C)的水平以及血清和肝脏丙二醛(MDA)水平,评价BD-TAS对高血脂症大鼠血脂代谢和肝脏保护作用。结果:以高脂饲料喂养大鼠8周后,与NC组相比,HC组TC,TG,HDL-C和LDL-C均升高且有显著性差异(P<0.01),成功复制了混合型高脂血症大鼠模型。以不同剂量BD-TAS溶液ig后,各组血浆TC,TG水平与高脂模型组比较,在第2,4,6周具有显著性差异(P<0.05或P<0.01);与NC组和HC比较,BD-TAS低、中剂量组TC,TG水平降低明显(P<0.05);BD-TAS高剂量组与低剂量组比较,TC,TG水平具有显著性差异(P<0.01)。与NC组比较,BD-TAS给药组血清MDA差异显著(P<0.05)。结论:BD-TAS摄入量越大,其改善血脂水平的效果越好,显示出明显的剂量依赖关系,提示毕岱总皂苷具有降血脂的作用,而且具有一定的肝保护作用。

Effects of Total Saponins of Medicago sativa on Blood Lipid Metabolism in Rats with Experimental Hyperlipidemia

Objective: To establish hyperlipidemia model of rats, to observe total saponins of Medicago sative(BD-TAS) on blood lipid metabolism in hyperlipidemia rats. Method : Sixty SD rats were randomly divided into six groups: normal control group (NC), high-lipid model group (HC), Xuezhikang capsule group, and BD-TAS group. All groups were induced with high fat diet for 8 weeks except NC, to establish hyperlipemia. NC and HC group were ig physiological saline, BD-TAS (4, 9, 12 g ·kg^-1), Xuezhikang Capsule group(0.5 g ·kg^-1). The contents of TC,TG,LDL-C,HDL-C and MDA were examined four times in the plasma after 0,2,4,6 weeks. Result : The result showed that with high fat diet after 8 weeks, compared with NC group, TC, TG, HDL-C and LDL-C were increased significantly (P < 0.05), so hyperlipidemia rat model was established successfully. BD-TAS of different dose groups, TC and TG in plasma were reduced after 2,4,6 weeks, compared with HC group (P<0.05). The level of TC in low-dose BD-TAS group was statistically significant compared with Xuezhikang group (P<0.05) and the levels of TC, TG in high-dose BD-TAS group were statistically significant compared with low-dose BD-TAS group (P<0.05). Conclusion : The levels of TC,TG and MDA decreased with the increased of BD-TAS dose, indicating a clear dose-effect relationship. BD-TAS is effective in modulating the blood lipid levels.